Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of TAS-102 in Chinese Patients with Solid Tumors
NCT02261532Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trifluridine + tipiracil in solid tumor, sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration of FTD at Day 12, Time to Reach Maximum Drug Concentration of FTD at Day 12 and 1 more. Started Sep 2014; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02261532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02261532.